By Tess Stynes 
 

Five Prime Therapeutics Inc. (FPRX) said GlaxoSmithKline PLC (GSK, GSK.LN) exercised its option for an exclusive global license to products related to an undisclosed muscle-disease target discovered by the clinical-stage biotechnology company.

Five Prime shares were recently trading at $12.07, up 4.9%.

Five Prime will receive a payment of $1.5 million in connection with the option exercise and is eligible for as much as $122.5 million in milestone payments.

Five Prime and Glaxo began a collaboration in 2010 to discover and develop drug targets for skeletal muscle diseases using Five Prime's platform.

Write to Tess Stynes at tess.stynes@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more GSK Charts.